Related Experiment Video
Updated: Apr 13, 2026
12:17
Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
Published on: March 17, 2008
16.1K
The nanochannel delivery system for constant testosterone replacement therapy.
Silvia Ferrati1, Eugenia Nicolov1, Erika Zabre1
1The Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
The Journal of Sexual Medicine
|May 2, 2015
Summary
The novel nanochannel delivery system (nDS) offers sustained testosterone release for over six months, effectively treating male hypogonadism. This innovative implantable system provides a promising alternative for long-term testosterone replacement therapy.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Drug Delivery Systems
Background:
- Testosterone replacement therapy aims to alleviate hypogonadism symptoms through physiological supplementation.
- Current methods may not consistently provide long-term, stable testosterone levels.
Purpose of the Study:
- To evaluate the implantable nanochannel delivery system (nDS) as a novel strategy for sustained testosterone release.
- To assess the efficacy of nDS for long-term, constant delivery of testosterone.
Main Methods:
- Developed a testosterone ester formulation (F1) for nanochannel delivery.
- Conducted a 6-month in vivo study in castrated rats using nDS-F1 implants and polymeric pellets.
- Measured plasma testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels.
Main Results:
- nDS-F1 implants demonstrated sustained in vivo release of testosterone over 6 months.
- Achieved stable, clinically relevant plasma testosterone levels.
- Significantly reduced LH and FSH levels, confirming testosterone's biological activity.
Conclusions:
- nDS-F1 implants represent a novel approach for treating male hypogonadism.
- The system provides sustained and effective testosterone delivery.
- Further research is warranted for clinical translation.
More Related Videos
Related Concept Videos
01:18Transdermal Drug Delivery Systems
180
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
180
01:26Oral Drug Delivery Systems: Continuous-Release Systems
255
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
255
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
133
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
133
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
103
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
103
01:21Intrauterine Drug Delivery Systems
150
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
150
01:24Modified-Release Drug Delivery Systems: Site-Targeted
141
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
141